---
marp: true
theme: default
paginate: true
title: Medicinal Chemistry of Benzodiazepine Sedative-Hypnotics
author: PHA 548 â€“ Pharmacology & Medicinal Chemistry
---

# ðŸ§¬ Medicinal Chemistry of Benzodiazepine Sedative-Hypnotics

**Course:** PHA 548 Pharmacology & Medicinal Chemistry  
**Reference:** *Foyeâ€™s Principles of Medicinal Chemistry, 8th Ed.*

---

## ðŸŽ¯ Learning Objectives

By the end of this 75â€“90 minute lecture, you should be able to:

1. Explain how benzodiazepines interact with the GABAA receptor at the Î±â€“Î³ interface.  
2. Analyze key SAR features that govern affinity, potency, and subtype preference.  
3. Predict pharmacokinetic behavior from structural modifications.  
4. Evaluate design improvements that led to newer agents such as remimazolam.

---

## ðŸ§  GABAA Receptor & Benzodiazepine MOA

- GABAA is a **pentameric ligand-gated Clâ» channel**  
  - Typical stoichiometry: **2Î± + 2Î² + 1Î³**
- Benzodiazepines bind at the **Î±â€“Î³ subunit interface**  
- They **do not** activate the receptor alone  
  - They **enhance GABAâ€™s effect** by increasing the **frequency** of Clâ» channel openings  
- Result: **Neuronal hyperpolarization** and reduced excitability

---

## Î± Subunit Selectivity

| Î± Subunit | Primary Functional Effect |
|----------|---------------------------|
| Î±1       | Sedation, anterograde amnesia, anticonvulsant |
| Î±2 / Î±3  | Anxiolysis, muscle relaxation |
| Î±5       | Cognitive effects / memory impairment |

> Medicinal chemistry takeaway: small structural changes can bias activity toward Î±1 vs Î±2/3/5â€“containing receptors.

---

## Required Benzodiazepine Pharmacophore

**Core scaffold: 5-phenyl-1,4-benzodiazepine-2-one**

Key features:

- **Ring A (benzene)** with **C7 electronegative substituent**  
- **Ring B (diazepine)** with **N1â€“C2 carbonyl**  
- **Ring C (C5 phenyl)** providing an aromatic Ï€-system

---

![Benzodiazepine backbone and sedative-hypnotic benzodiazepines (Foye Fig. 12.6)](figures/figure_12.6.jpg)

*5-Phenyl-1,4-benzodiazepin-2-one backbone and sedative-hypnotic benzodiazepines (Flurazepam, Quazepam, Triazolam, Estazolam, Temazepam).*

---

## Pharmacophore â€“ Functional Elements

| Feature                          | Why Itâ€™s Required                                  |
|----------------------------------|----------------------------------------------------|
| **C7 electronegative group**     | Increases GABAA affinity via electronic effects    |
| **C5 phenyl ring (Ring C)**      | Aromatic Ï€â€“Ï€ stacking in binding pocket           |
| **N1â€“C2 carbonyl**               | H-bond anchoring at BZD binding site              |

Color convention (for SAR overlays in notes):  
- ðŸŸª Ring Aâ€ƒâ€ƒðŸŸ¦ Ring Bâ€ƒâ€ƒðŸŸ¥ Ring C

---

## SAR Overview â€“ Key Sites

| Site                 | MedChem Rule                        | Effect                              |
|----------------------|-------------------------------------|-------------------------------------|
| **C7 (Ring A)**      | Electronegative (Cl, Br, NOâ‚‚)       | Essential for high potency          |
| **C5 phenyl (Ring C)** | Must remain planar and aromatic  | Required for agonist activity       |
| **o-halogenation**   | 2â€²-F / 2â€²-Cl on Ring C             | â†‘ Lipophilicity, â†‘ CNS penetration |
| **p-substitution**   | Bulky groups at para position       | Steric clash â†’ â†“ binding / inactive |
| **C3â€“OH group**      | Introduces conjugation site         | Shorter duration (Phase II)         |
| **Triazolo/imidazo fusion** | Metabolic shielding        | â†‘ Potency, â†“ active metabolites     |
| **Ester moiety** (remimazolam-like) | Esterase substrate | Ultra-short, hydrolysis-driven tÂ½   |

---

## SAR â†’ Pharmacokinetics Theme

- **Lipophilicity** drives:
  - CNS penetration  
  - Tissue distribution  
  - Duration of action

- **Metabolic â€œsoft spotsâ€**:
  - Exposed N-alkyl chains â†’ CYP N-dealkylation â†’ active metabolites  
  - Aromatic rings â†’ hydroxylation â†’ Phase II conjugation

- **Design philosophy** for newer agents:
  > Replace **oxidative liabilities** with **hydrolytic or conjugation liabilities**.

---

## Case SAR Examples â€“ Classical BZDs

- **Flurazepam**
  - N-alkyl chain at N1  
  - Lipophilic o-halogenated phenyl ring  
  - â†’ Multiple long-acting active metabolites

- **Quazepam**
  - Very lipophilic and sulfur-containing moiety  
  - â†’ Long tÂ½ and metabolite accumulation

- **Triazolam / Estazolam**
  - **Fused triazole ring** reduces oxidative metabolism  
  - More predictable, shorter duration

- **Temazepam**
  - **C3â€“OH** promotes direct glucuronidation  
  - Minimizes Phase I metabolism, short duration

---

## Metabolism of Flurazepam & Quazepam

![Metabolism of flurazepam and quazepam (Foye Fig. 12.7)](figures/figure_12.7.jpg)

*Note the N-dealkylation and formation of long-acting active metabolites.*

---

## PK & Metabolism Comparison

| Drug        | Key SAR Feature       | Primary Metabolic Route    | PK Outcome                         |
|-------------|-----------------------|----------------------------|------------------------------------|
| Flurazepam  | N-alkyl at N1         | CYP3A4 N-dealkylation      | Very long-acting active metabolites |
| Quazepam    | Highly lipophilic     | CYP3A4 / CYP2C9 oxidation  | Prolonged duration, accumulation   |
| Estazolam   | Triazolo fusion       | CYP3A4 hydroxylation       | Intermediate tÂ½, limited actives   |
| Triazolam   | Compact triazolo BZD  | Oxidation â†’ conjugation    | Short-acting, minimal accumulation |
| Temazepam   | C3â€“OH                 | Direct glucuronidation     | Rapid clearance, short duration    |
| Remimazolam | Ester-containing side chain | Esterase hydrolysis | Ultra-short duration, predictable  |

---

## Remimazolam â€“ Design Rationale

- Maintains **benzodiazepine pharmacophore** for GABAA binding  
- Incorporates a **cleavable ester** in the side chain  
  - Substrate for **tissue carboxylesterases**  
  - Rapid inactivation to non-BZD metabolite  
- Minimizes dependence on CYP enzymes

> Medicinal chemistry goal: **tight temporal control** of sedation.

---

## Active Learning â€“ Structural Prediction

For each structural change, predict:

1. Effect on receptor binding (â†‘, â†“, or inactive)  
2. Effect on PK (shorter, longer, or unchanged tÂ½)  

Examples:

- Remove the **C7-Cl** and replace with H  
- Add a **bulky para-substituent** on the C5 phenyl ring  
- Introduce a **C3â€“OH** group  
- Fuse a **triazole ring** onto Ring B  
- Add an **ester side chain** similar to remimazolam

Discuss in pairs, then we review as a group.

---

## Key Takeaways

- Benzodiazepines require:
  - **C7 electronegative substitution**
  - **C5 phenyl ring**
  - **N1â€“C2 carbonyl**

- SAR modifications can:
  - Tune **affinity and selectivity**  
  - Dramatically change **tÂ½ and metabolic fate**

- Newer drugs (e.g., **remimazolam**) are engineered using:
  - Ester **hydrolysis** instead of oxidative pathways  
  - Design for **predictable, ultra-short** sedation

---

## Molecular Note â€“ Flumazenil

- **Competitive antagonist** at the same benzodiazepine Î±â€“Î³ binding site  
- Recognizes the **same pharmacophore** but lacks intrinsic efficacy

---

# Questions?

Thank you!  
Next session: Non-benzodiazepine GABAA modulators and sedative-hypnotic SAR.

